Evidence map›Paper›PMID 35173612›Full record

ArticleFrontiers in pharmacology2021

Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis.

Xiaoli Du, Qianqian Tao, Hongxia Du, Zhenbang Zhao, Yu Dong, Shuang He, Rui Shao, Yule Wang, Wenrun Han, Xintong Wang and 1 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Roles of LncRNA ARSR in tumor proliferation, drug resistance, and lipid and cholesterol metabolism.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoli DuInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Qianqian TaoInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Hongxia DuInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zhenbang ZhaoDepartment of Pharmacy, Inner Mongolia Medical College, Hohhot, China.
Yu DongInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Shuang HeInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Rui ShaoInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yule WangInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Wenrun HanInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xintong WangInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yan ZhuInstitute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Tianjin University of Traditional Chinese Medicine · CNInner Mongolia Medical University · CNTianjin International Joint Academy of Biomedicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.638298.].

Indexed as

human kidney HEK293 cellshypertension-induced kidney damageinflammatory responseperiostinTGFÎ2/SMAD signaling pathway

Identifiers

PMID35173612
PMCPMC8841330
OpenAlexW4210401736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.